Subcutaneous panniculitis-like T-cell lymphoma: Complete remission with fludarabine

R. S. Go, H. Gazelka, J. D. Hogan, S. M. Wester

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an uncommon type of cutaneous lymphoma with an aggressive natural history. It generally carries a poor prognosis despite standard anthracycline-based chemotherapy. The optimum therapy is unknown. We report the case of a 66-year-old man with CD4/CD8 double negative SPTCL who achieved a complete remission with single-agent fludarabine. He received a total of six cycles of fludarabine given at 25 mg/m2 daily for 5 days every 4 weeks. His skin ulcers started to heal within 2 weeks of the first cycle of chemotherapy and were completely healed before the fourth cycle. Unfortunately, he died suddenly of unknown cause 3 months after the completion of chemotherapy while remaining in complete remission. Our report suggests that fludarabine may be an active agent in SPTCL and deserves further study.

Original languageEnglish (US)
Pages (from-to)247-250
Number of pages4
JournalAnnals of hematology
Volume82
Issue number4
DOIs
StatePublished - Apr 1 2003

Keywords

  • Fludarabine
  • Subcutaneous panniculitis-like T-cell lymphoma

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Subcutaneous panniculitis-like T-cell lymphoma: Complete remission with fludarabine'. Together they form a unique fingerprint.

  • Cite this